EMA Withdrawn: Removab (catumaxomab) — Neovii Biotech GmbH

View source ↗

Summary

Removab (catumaxomab) has been withdrawn from the market by Neovii Biotech GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Cancer

Drugs mentioned

• Removab (catumaxomab)

Snippet

Status: Withdrawn. Therapeutic area: Ascites;Cancer. MAH: Neovii Biotech GmbH. Decision date: 02/06/2017